Diabetic foot infection: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| Line 4: | Line 4: | ||
*Typically polymicrobial, including: |
*Typically polymicrobial, including: |
||
**[[Staphylococcus |
**[[Staphylococcus aureus]], which is by far the most common cause of monomicrobial infections |
||
**[[Coagulase-negative staphylococci]] |
|||
**[[Streptococcus species]] |
**[[Streptococcus species]] |
||
**[[ENterococcus species]] |
|||
**[[Proteobacteria]] (Gram-negative bacterial genus that includes enterics) |
|||
**[[ |
**[[Enterobacteriaceae]] |
||
**[[Pseudomonas aeruginosa]] |
|||
**[[Anaerobes]], including [[Bacteroides fragilis]] |
|||
*Anaerobes are more likely to be involved in deeper, more chronic ulcers |
*Anaerobes are more likely to be involved in deeper, more chronic ulcers |
||
==Management== |
==Management== |
||
{| class="wikitable" |
|||
!Severity |
|||
!Common Pathogens |
|||
!Antibiotics |
|||
!Notes |
|||
|- |
|||
| rowspan="7" |Mild |
|||
| rowspan="5" |methicillin-susceptible [[Staphylococcus aureus]], [[Streptococcus species]] |
|||
|[[dicloxacillin]] |
|||
|qid dosing and very narrow-spectrum |
|||
|- |
|||
|[[clindamycin]] |
|||
|active against MRSA but higher risk of [[CDAD]] |
|||
|- |
|||
|[[cephalexin]] |
|||
|qid dosing |
|||
|- |
|||
|[[levofloxacin]] |
|||
|not as effective against [[Staphylococcus aureus]] |
|||
|- |
|||
|[[amoxicillin-clavulanic acid]] |
|||
|broad-spectrum, includes anaerobic coverage |
|||
|- |
|||
| rowspan="2" |methicillin-resistant [[Staphylococcus aureus]] |
|||
|[[doxycycline]] |
|||
|uncertain activity against streptococci |
|||
|- |
|||
|[[TMP-SMX]] |
|||
|uncertain activity against streptococci |
|||
|- |
|||
| rowspan="13" |moderate or severe |
|||
| rowspan="9" |[[MSSA]], [[Streptococcus species]], [[Enterobacteriaceae]], [[anaerobes]] |
|||
|[[levofloxacin]] |
|||
|suboptimal against MSSA |
|||
|- |
|||
|[[cefoxitin]] |
|||
| |
|||
|- |
|||
|[[ceftriaxone]] |
|||
| |
|||
|- |
|||
|[[ampicillin-sulbactam]] |
|||
| |
|||
|- |
|||
|[[moxifloxacin]] |
|||
| |
|||
|- |
|||
|[[ertapenem]] |
|||
| |
|||
|- |
|||
|[[tigecycline]] |
|||
| |
|||
|- |
|||
|[[Fluoroquinolones|fluoroquinolone]] with [[clindamycin]] |
|||
| |
|||
|- |
|||
|[[imipenem-cilastatin]] |
|||
| |
|||
|- |
|||
| rowspan="3" |MRSA |
|||
|[[linezolid]] |
|||
| |
|||
|- |
|||
|[[daptomycin]] |
|||
| |
|||
|- |
|||
|[[vancomycin]] |
|||
| |
|||
|- |
|||
|[[Pseudomonas aeruginosa]] |
|||
|[[piperacillin-tazobactam]] |
|||
| |
|||
|} |
|||
*Osteomyelitis |
*Osteomyelitis |
||
Revision as of 20:19, 13 January 2021
Background
Microbiology
- Typically polymicrobial, including:
- Staphylococcus aureus, which is by far the most common cause of monomicrobial infections
- Coagulase-negative staphylococci
- Streptococcus species
- ENterococcus species
- Enterobacteriaceae
- Pseudomonas aeruginosa
- Anaerobes, including Bacteroides fragilis
- Anaerobes are more likely to be involved in deeper, more chronic ulcers
Management
| Severity | Common Pathogens | Antibiotics | Notes |
|---|---|---|---|
| Mild | methicillin-susceptible Staphylococcus aureus, Streptococcus species | dicloxacillin | qid dosing and very narrow-spectrum |
| clindamycin | active against MRSA but higher risk of CDAD | ||
| cephalexin | qid dosing | ||
| levofloxacin | not as effective against Staphylococcus aureus | ||
| amoxicillin-clavulanic acid | broad-spectrum, includes anaerobic coverage | ||
| methicillin-resistant Staphylococcus aureus | doxycycline | uncertain activity against streptococci | |
| TMP-SMX | uncertain activity against streptococci | ||
| moderate or severe | MSSA, Streptococcus species, Enterobacteriaceae, anaerobes | levofloxacin | suboptimal against MSSA |
| cefoxitin | |||
| ceftriaxone | |||
| ampicillin-sulbactam | |||
| moxifloxacin | |||
| ertapenem | |||
| tigecycline | |||
| fluoroquinolone with clindamycin | |||
| imipenem-cilastatin | |||
| MRSA | linezolid | ||
| daptomycin | |||
| vancomycin | |||
| Pseudomonas aeruginosa | piperacillin-tazobactam |
- Osteomyelitis
- Traditionally, 6 weeks of parenteral therapy
- May be able to shorten to 3 weeks if adequately debrided, based on more recent evidence1
Further Reading
- The Neuropathic Diabetic Foot Ulcer Microbiome IsAssociated With Clinical Factors. Diabetes. 2013;62:923-930.
References
- ^ Karim Gariani, Truong-Thanh Pham, Benjamin Kressmann, François R Jornayvaz, Giacomo Gastaldi, Dimitrios Stafylakis, Jacques Philippe, Benjamin A Lipsky, İlker Uçkay. Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1758.
